Monte Rosa Therapeutics has dosed the first participants in the Phase I trial of the NEK7-directed molecular glue degrader (MGD), MRT-8102.

Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.

New guidelines recommended by WHO will need to be backed with funding to be implemented at scale in affected communities.

AstraZeneca's Tagrisso combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS).

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

Industry experts have provided insight into how oncology clinical trials can be designed for success from the outset and rendered as patient-centric as possible.

Ocugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, OCU410ST.

Bristol Myers Squibb (BMS) has revealed that its Phase III trial assessing Reblozyl with JAKi therapy did not meet its primary goal.

Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy treatment.

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

Velocity Clinical Research partnered with Palantir Technologies for streamlining and automating payment reconciliation processes in trials ...